Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17067-72. doi: 10.1073/pnas.0804868105. Epub 2008 Oct 27.

    A p38 MAPK-MEF2C pathway regulates B-cell proliferation.

    Source

    Cardiovascular Research Institute and Department of Biochemistry and Biophysics, University of California, San Francisco, CA 94158-2517, USA.

    Abstract

    B lymphocytes are an integral part of the adaptive immune system. On antigen binding to the B-cell receptor (BCR), B cells rapidly proliferate and differentiate into antibody-secreting plasma cells. The p38 mitogen-activated protein kinase (MAPK) pathway functions downstream of the BCR to control cell proliferation, but the transcriptional effectors of this pathway in B cells have remained elusive. In the present study, we inactivated Mef2c exclusively in B cells by conditional gene targeting in mice. Loss of MEF2C function resulted in a reduced immune response to antigen, defective germinal center formation, and a severe defect in B-cell proliferation, and we show that MEF2C regulates proliferation in response to BCR stimulation via the p38 MAPK pathway. p38 directly phosphorylates MEF2C via three residues in the C-terminal transactivation domain, establishing MEF2C as a direct transcriptional effector of BCR signaling via p38 MAPK.

    PMID:
    18955699
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2579379
    Free PMC Article

    Images from this publication.See all images (6)Free text

    Fig. 1.
    Fig. 3.
    Fig. 5.
    Fig. 2.
    Fig. 4.
    Fig. 6.

      Supplemental Content

      Icon for HighWire Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk